Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | FGFR2 | P21802 | 17/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 17/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 16/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 11/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23917227 | 0.87 | FGFR2 (0.58) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL16655794 | 0.84 | BTK (0.59) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL23917473 | 0.81 | FGFR2 (0.45) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL16655589 | 0.78 | BTK (0.57) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL16665823 | 0.76 | BTK (0.54) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL16655511 | 0.76 | BTK (0.54) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL16701939 | 0.74 | BTK (0.56) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL23917487 | 0.74 | FGFR1 (0.52) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL16655461 | 0.73 | BTK (0.59) | BTKFGFR2FGFR1FGFR3FGFR4 | |
| SCHEMBL16702040 | 0.73 | BTK (0.54) | BTKFGFR2FGFR1FGFR3FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | BTK 1/4885FGFR2 1759/4885FGFR1 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.